News Manufacturing issues mar ITM's radiopharma filing, says FDA ITM's first attempt to score FDA approval for one of its radiopharma therapies has been knocked back by the agency.
News Ex-BioNTech execs launch 'AI-native' cancer company Two senior executives formerly at BioNTech have launched a new biotech, Bios Life, that they call "an AI-native cancer surveillance company."
News Sobi adds rare lymphoma drug with $580m Innate tie-up Sobi chief executive Guido Oelkers is preparing his exit, but is still cutting deals, licensing a lymphoma drug from Innate for up to $580m.
R&D Clinical Trials Round-Up: May and June 2026 May and June delivered a plethora of clinical trial updates. In the build-up to ASCO in June, our inbox was overflowing with oncology trial results.
News TransThera's resistant biliary cancer drug cleared in China TransThera's Yochanra has been cleared in China as the world's first drug that can overcome resistance to FGFR inhibitors in cholangiocarcinoma.
News Third time lucky for Replimune as FDA OKs melanoma drug At its third attempt, Replimune has finally won FDA approval for its advanced melanoma treatment RP1, now named Tudriqev and its first product.
News Beacon's XLRP gene therapy set for filing after phase 3 win Beacon is preparing to file for approval of its gene therapy for X-linked retinitis pigmentosa, after reporting encouraging phase 3 data.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
